Ionis Pharmaceuticals shares plunged 14.0% in pre-market trade to $72.60 after the company and partner AstraZeneca disclosed that the Phase 3 CARDIO-TTRansform trial of eplontersen did not achieve its primary efficacy endpoint. The study measured a composite outcome of cardiovascular mortality and recurrent cardiovascular events through Week 140 compared with placebo and failed to demonstrate a statistically significant benefit.
The CARDIO-TTRansform program was sizeable: 1,432 participants were enrolled across 130 sites in 20 countries, making it one of the largest clinical trials ever undertaken in transthyretin-mediated amyloid cardiomyopathy, or ATTR-CM. While the overall trial outcome missed the prespecified primary endpoint, a pre-specified subgroup analysis reported a nominally significant result for patients on eplontersen monotherapy. Company statements also noted that the safety profile observed in the study remained consistent with prior data for the drug.
The failed readout represented a major setback for Ionis because management had positioned CARDIO-TTRansform as a cornerstone of the company’s 2026 growth narrative. Executives had described the trial as a potential path to broaden eplontersen’s commercial reach beyond its existing WAINUA approval for hereditary transthyretin-mediated amyloid polyneuropathy. With the primary endpoint unmet, the prospect of eplontersen capturing significant market share in ATTR-CM is now uncertain.
Prior to the announcement, Wall Street sentiment toward Ionis had been generally upbeat, with analysts maintaining average price targets substantially above the post-announcement share price. That optimism was tied in part to the expectation that a positive CARDIO-TTRansform outcome would establish eplontersen as a competitive option in a growing cardiomyopathy market.
The broader competitive landscape in ATTR-CM matters to how investors interpreted the news. Alnylam Pharmaceuticals already holds an approved indication in ATTR-CM for its RNAi therapy Amvuttra (vutrisiran), which has gained commercial traction. The negative CARDIO-TTRansform result effectively reduces the near-term competitive pressure that eplontersen posed in cardiomyopathy, a development that could be favorable to existing players such as Alnylam, as well as other companies with interest in the indication, including BridgeBio and Pfizer.
Market context underscored the idiosyncratic nature of the selloff. The S&P 500 was slightly lower and the Dow Jones declined, while the Nasdaq posted a modest gain on the session, indicating that the sharp move in Ionis shares was driven by company-specific trial news rather than a broad market shift.
The combination of a high-profile Phase 3 miss in a large and commercially relevant patient population, the loss of a major clinical catalyst that underpinned bullish analyst views, and a competitive ATTR-CM market with an established rival therapy converged to produce one of the steepest single-session declines in Ionis’s recent trading history. The drop erased gains from prior months and pulled the stock below its 52-week high of $86.74 reached earlier in the day.
For shareholders and market participants, the immediate implications include reevaluation of the commercial outlook for eplontersen and reassessment of analyst models that had counted on CARDIO-TTRansform as a revenue driver. The longer-term path for the drug in ATTR-CM will depend on further analysis of the trial data, regulatory considerations, and any strategic responses by Ionis and AstraZeneca, none of which were detailed beyond the trial readout in the companies’ announcement.